Real World Data to Provide Real World Evidence

• 6632 · PDF Trends in treatment and survival among patients with glioblastoma in the United States, 2000 to 2020: A population-based SEER analysis Jianan Chen, Qiong Wu, Catherine Boldig, Rob J B Macaulay, Arnold Etame
• 6633 · PDF PD-L1 expression-dependent efficacy of first-line immune checkpoint inhibitor plus chemotherapy in advanced gastric and gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis of phase III trials Jialun Lyu, Zhenzhen Zhang, Krishnapriya Thangaretnam, Md Obaidul Islam, Jason Tang, Sabine Denize, Nadeem Bhat, Shoumin Zhu, Heng Lu, Dunfa Peng, Wael El Rifai, Zheng Chen
• 6634 · PDF Real-world comparative outcomes of nivolumab + ipilimumab vs. atezolizumab + bevacizumab in advanced hepatocellular carcinoma: A TRINETX study Sameh Gomaa, Abdelrahman Omara, Hatem Ahmed, Imad Alabdul Razzak, Potdar Rashmika, Kuang-Yi Wen
• 6635 · PDF Evaluation of stage IV PTCL, NOS of the liver and gastrointestinal tract using a large national cancer database Olivia Davis, Taha Al-Juhaishi, Ryan Wilcox
• 6636 Clinical outcomes of stage IV mucinous adenocarcinoma based on primary sites Wongi Woo, Seoin Kim, Jongwoo Kim, Vincent Lopez, Yeena Lee, Kirun Chohan, Young Kwang Chae
• 6637 · PDF Real world outcomes for patients with KRAS G12D -mutated non-small cell lung cancer: A University of California Health Data Warehouse retrospective analysis Jingtong Liang, Tali Azenkot, Sandip Patel
• 6638 · PDF Real-World evidence of eflapegrastim (efla) usage in patients with gastrointestinal (GI) malignancies Howard Franklin, Jeffrey Crawford, John H. Baird, Kenneth Crist, Vincent Marino, Neil Shah, Lee S. Schwartzberg
• 6639 · PDF Impact of preexisting heart disease on survival and postoperative outcomes in pancreatic cancer: A TriNetX analysis Charlotte Burch, Jacob Lambdin, William Royster, Adam Khader, Leopoldo Fernandez, Raphael Louie, Ricardo Bello, Jose G. Trevino
• 6640 · PDF Geriatric nutritional risk index at diagnosis predicts survival in pancreatic cancer Christina Grinstead, Saunjoo Yoon
• 6642 · PDF Metabolic predictors of chemotherapy response in pancreatic cancer Parnian Naji, Jordan Winter
• 6643 · PDF Incidence and outcomes of brain metastasis in ER-low breast cancer: Insights from a National Cancer Database (NCDB) Aanika B. Warner, Sarah Darmon, Jeremy Perkins, Matt Nealeigh, Craig D. Shriver, Stan Lipkowitz, Kangmin Zhu, Takeo Fujii
• 6644 · PDF Adjuvant dose-dense chemotherapy is not associated with improved recurrence-free survival in early-stage, node-negative, HER2-negative breast cancer Jonathan Shpigelman, Tasnem Alsebai, Kathy Robinson, Aum Nimavat, Ricardo Cossyleon, Krishna Rao
• 6645 · PDF Practice patterns impacting relative dose intensity of adjuvant capecitabine among triple negative breast cancer patients with residual disease following neoadjuvant chemotherapy Andrea House, Pratik Thakur, Blair Hoeting, Ruth Johnson, Brittany Sandoval, Julie Stephens, Daniel G. Stover, Sagar Sardesai, Tanun Jitwatcharakomol, Sasha Beyer, Arya M. Roy, Nerea Lopetegui-Lia, Dionisia M. Quiroga, Ashley P. Davenport, Gilbert Bader, Nicole O. Williams, Robert Wesolowski, Margaret E. Gatti-Mays, Kai C. C. Johnson
• 6646 · PDF Impact of histology subtypes (ductal, lobular, and mixed ductal/lobular) on pathological complete response (pCR) following neoadjuvant chemotherapy (NAC) and chemoimmunotherapy (NACI) for estrogen receptor low (ER-low) HER2-negative breast cancer Kai C. C. Johnson, Brandon Slover, Yengeniya Gokun, Dionisia M. Quiroga, Sagar Sardesai, Sachin Jhawar, Nerea Lopetegui-Lia, Arya M. Roy, Gilbert Bader, Ashley P. Davenport, Nicole O. Williams, Robert Wesolowski, Margaret E. Gatti-Mays, Daniel G. Stover
• 6647 MCM2 and the origin licensing complex: A putative node of ER+/HER2- breast cancer therapy resistance Alekya Raghavan, Rosemary N. Plagens, Cynthia X. Ma, Stephanie Graff, Maryam Lustberg, Andrew Elliott, George W. Sledge, C. Kent Osborne, Mothaffar F. Rimawi, Ahmed Elkhanany, Rachel Schiff
• 6648 · PDF Association between area deprivation index (ADI) and treatment persistence (TP) with CDK4/6 inhibitors (CDK4/6i)in HR+/HER2- breast cancer Michelle L. Caetano, Jessica Liu, Britny R. Brown, Guannan Gong, Sameer Pandya, Salma Taghzout, Mariah Ramos, Edward Tupper, Annette Hood, Michael Zummo, Robert Legare, Jing Du, Maryam Lustberg
• 6649 Comparative risk of secondary central nervous system metastases in metastatic non-small cell lung cancer: A real-world propensity-matched analysis of pembrolizumab vs atezolizumab monotherapy conducted on TriNetX Umer Rizwan, Athar Nawab, Syed Najafi, Karandeep Bawa, Fnu Muhibullah, Christian Kaftanic, Sunanda Tah, Sabir Hussain
• 6650 · PDF Safety and efficacy of belzutifan for Von Hippel-Lindau disease-associated tumors Peixi Ge, Mohamed Atta, Nityasree Srialluri
• 6651 · PDF Characterizing the risk of infections with T-cell engagers in multiple myeloma Lindsay Fogel, Harsh Parmar, Shucen Wan, Adolfo Aleman, Pooja Phull, David Vesole, David S. Siegel, Rena Feinman, Claire L. Carter, Noa Biran
• 6652 · PDF Viral hepatitis paradox: Better outcomes in geriatric HCC transplant patients Ewan Kim, Sungsu Park, Amy Choi
• 6653 · PDF Hepatosplenic T-cell lymphoma gamma-delta versus alpha-beta: A comparative study of clinicopathologic features and outcomes Philip A. Haddad, Sireesha Vutukuri, Ankita Gupta
• 6654 · PDF Assessing skin cancer risk in systemic sclerosis patients with organ transplantation: A cohort study Ruhi Kanwar, Ellen Anshelevich, Goranit Sakunchotpanit, Kevin Fettel, Vinod E. Nambudiri
• 6655 · PDF Characterization of adverse cutaneous effects in the setting of ponatinib, bosutinib, andasciminib for chronic myeloid leukemia patients Ruhi Kanwar, Juna Khang, Goranit Sakunchotpanit, Ruhi Nayak, Nicole R. LeBoeuf, Vinod E. Nambudiri

在完整检索应用中浏览本分会场 →